Netherlands· NL-84e9f4fb6036

Urispas, omhulde tabletten 200 mg

A flavoxate product containing flavoxaathydrochloride, registered in Netherlands by Recordati Ireland Ltd. (Co. Cork). The same ATC class is registered in 7 of our 19 countries.

ATC G04BD02

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about flavoxaathydrochlorideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Flavoxate is registered in 7 of 19 countries.

Countries holding a registration under ATC G04BD02 (flavoxate), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
3 of them publish a price we can compare per daily dose

Search flavoxate products by name

Flavoxate · ATC G04BD02

7 / 19 countries

Belgiumprice
Germany
Ireland
Netherlands
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of flavoxate costs, country by country.

Normalised to the WHO defined daily dose (0.8 g), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Flavoxate · price per daily dose (0.8 g)

USD · FX 28 Sept 2026

CH Switzerland$2.26

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: FLAVOXAATHYDROCHLORIDE
Manufacturer: Recordati Ireland Ltd. (Co. Cork)
Country: Netherlands (NL)
ATC code: G04BD02
ATC class: Flavoxate
Defined daily dose: 0.8 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
08322

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

132 interactions on record for flavoxate.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check flavoxate against other medicines How interaction checks work

Flavoxate · interactions on record

132 records

3 severe
89 moderate
1 minor

Most severe, free to view

Potassium chlorideA12BA01severe
Potassium citrateA12BA02severe
Potassium chlorideB05XA01severe
DicycloverineA03AA07moderate

39 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Flavoxate in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All flavoxate products

Authorised across Europe · EMA

The same active substance is authorised in 10 EEA countries. Names it is sold under:

Belgium · Urispas
Germany · Spasuret 200 Mg
Spain · Uronid
France · Urispas
United Kingdom (Northern Ireland) · Urispas
Ireland · Urispas
Italy · Genurin
Lithuania · Urispas
Luxembourg · Urispas
Portugal · Urispás

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/9b84af14-8b13-4bd4-b79f-b1d055ea025f
GET /v1/drugs/9b84af14-8b13-4bd4-b79f-b1d055ea025f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Omhulde tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h08322_smpc.pdf",
  "strength": null,
  "atc_label": "Flavoxate",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg08322",
  "excipients": [
    "ARABISCHE GOM (E 414)",
    "CASTOROLIE",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "GELATINE (E 441)",
    "LACTOSE 1-WATER",
    "MAGNESIUMCARBONAAT (E 504 (I))",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMZETMEELGLYCOLAAT",
    "POVIDON (E 1201)",
    "SACCHAROSE",
    "SCHELLAK (E 904)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)",
    "WALSCHOT"
  ],
  "substances": [
    "FLAVOXAATHYDROCHLORIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h08322.pdf",
  "authorised_at": "1979/11/27",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "08322",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about flavoxate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console